Regulatory · Clinical trials · Pharmacovigilance · Quality · Market access, for EU & US pharma, from the official sources
Noema Pharma's oral mGluR5 modulator, already on the FDA's Fast Track, now also carries orphan status for the rare and painful neuropathic condition.
The US suit against a $3.5bn merger of the two largest vet distributors is an antitrust case, but animal-health PV teams should check how safety information moves through the channel.
Medicare is paying $1,938.01 per EsoGuard test, but case-by-case coverage with a MolDX reconsideration pending is a signal to read carefully, not a foundation to build on.
Health Canada's Type II recall of Vercise clinician programmer instructions is narrow, but it shows how a labelling correction can ripple into protocols, training and site files.
Unaudited results to 30 September 2026 show third-quarter revenue of $129.0M, down from $135.6M, while nine-month net income reached $50.1M.
The company says recruitment is finished for the randomised, placebo-controlled multiple-dose part of its Phase I/IIa study of a non-hallucinogenic psychedelic-derived candidate.
Galmed R&D, a subsidiary of Eocene, says a new lipid nanoparticle formulation of Aramchol is designed to reach the tumour microenvironment; the work is preclinical.
Pooled, blinded 12-week data from 24 patients show 33% with improved FVC and no treatment-related serious adverse events, though the company says no treatment effect can be inferred.
The US biotech posted a $21.8 million third-quarter net loss and says its cash runway extends into the first half of 2028.
The company says it has submitted a registrational protocol for belapectin in MASH cirrhosis with portal hypertension, and reports cash it expects to last through June 2027.
The company's latest investor deck reports first dosing in the registrational study, a 43% confirmed response rate in earlier-line data, and an obesity candidate, CRB-913, with about $115M in cash.
Interim results presented at SNO show high concordance with contrast-enhanced MRI and no serious treatment-emergent adverse events, with specificity data due in the first quarter of 2027.
Eloxx Pharmaceuticals reported Q3 2026 results, with exaluren now in a Phase 2b Alport trial, an FDA-cleared ADPKD study, and cash guided into 2028.
The company's investor presentation covers its sole candidate, an unapproved oncolytic immunotherapy for NMIBC, citing no Grade 3 or higher treatment-related adverse events across three studies.
Apnimed says its new drug application for AD109 (proposed name Oxnimbi) in adult obstructive sleep apnoea remains under FDA review, as it reports a Q3 net loss of $29.5m.
XORTX Therapeutics says manufacturing and packaging of drug supply for its oxypurinol tablet gout study is finished, ahead of planned Health Canada and FDA filings.
The company reported no third-quarter revenue and $3.1 million in cash, and carried out a 1-for-30 reverse stock split to address Nasdaq's minimum bid price rule.
The agency has accepted the phosphate binder resubmission after a June 2026 complete response letter that cited deficiencies at the original drug product vendor.
A proxy supplement filed with the SEC revises outstanding share figures after preferred shares were converted, changing quorum and voting-power numbers for the Dutch-to-Luxembourg move.
Unaudited Q3 2026 statements show a $32.2M quarterly loss, $45.8M in cash and a roughly $50M note from a related party.
The agency found HARMONi's progression-free survival gain, without a significant overall survival improvement, did not show substantial evidence of effectiveness or a positive benefit-risk profile.
InMed Pharmaceuticals closed its two-step merger with Mentari Therapeutics on 6 November and adopted the Mentari name; lead anti-PACAP antibody MT-001 is in a New Zealand Phase 1 trial.
The Canadian cannabis company says its shares closed below US$1.00 for 30 consecutive business days. The notice does not affect trading on Nasdaq or the TSX.
Dr. Reddy's says the US regulator has classified its Hyderabad formulations plant inspection as VAI and considers the inspection officially closed.
Part A data for Annamycin plus cytarabine in relapsed or refractory AML are expected in the first quarter of 2027 and will guide dose selection for Part B.
Interim results for the gene therapy show falls in arrhythmia measures, and the company says FDA is open to a surrogate endpoint for accelerated approval.
The US gene therapy developer expects topline data in the second half of 2027 and says a BLA could be filed in the first half of 2028.
Invivyd reports $15.4 million in third-quarter Pemgarda net revenue and $126.4 million in cash, while Phase 3 DECLARATION data for VYD2311 are now timed differently following FDA discussions.
The Nasdaq-listed Zcash treasury company says a non-cash derivative gain drove its profit, while its Leap Therapeutics unit seeks funding or a partner for a colorectal cancer candidate.
The randomised, placebo-controlled study of the oral ITK/JAK3 inhibitor will enrol about 100 patients, starting with oral erosive disease, which holds FDA Fast Track status.
The US biotech reported Q3 results on 16 November 2026, with cash of $463.4 million, and said Alzheimer's psychosis data from VISTA are now expected in 2028.
Topline data show the deuterated psilocin candidate improved MADRS scores versus placebo as adjunctive therapy in adults with major depressive disorder, with a second pivotal readout due in Q4 2027.
The US biotech is relying on skin frataxin as a novel surrogate endpoint and expects the FDA's filing decision in early 2027, with approval targeted for mid-2027.
Helus Pharma has enrolled 223 patients in its Phase 3 study of HLP003 in major depressive disorder, while quarterly net loss widened to $103.1M.
Regulatory, quality and pharmacovigilance consulting for the pharmaceutical industry
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.